850649-62-6 Alogliptin Benzoate Treatment Of Type 2 Diabetes

Alogliptin benzoate is a serine protease two peptide peptidase IV (DPP- IV) inhibitor developed by Takeda company in japan.
This product can maintain the levels of glucagon like peptide 1 (GLP-1) and Glucose dependent insuli n-like growth polypeptide
(GIP) in vivo and promote the secretion of insuli n and thus exert hypoglycemic effect. A randomized, placebo-controlled clinical
trial results showed that, compared with placebo Agger gliptin monotherapy can significantly improve glycemic control in type 2
diabetes, did not increase the incidence of hypoglycemia,well tolerated. A Glenn Dean and the medicine composition is the sitagliptin,
vildagliptin asked the city after oral administration of effective specific DPP- IV inhibitors, provides a new choice of treatment for patients
with type 2 diabetes, and has wide application prospect.